Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma

Yasuharu Akasaki,Tetsuro Kikuchi,Sadamu Homma,Shigeo Koido,Toshifumi Ohkusa,Tetsunori Tasaki,Kazumi Hayashi,Hideo Komita,Nobuyuki Watanabe,Yuta Suzuki,Yohei Yamamoto,Ryosuke Mori,Takao Arai,Toshihide Tanaka,Tatsuhiro Joki,Takaaki Yanagisawa,Yuichi Murayama

Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma

2016

Yasuharu Akasaki
Tetsuro Kikuchi
Sadamu Homma
Shigeo Koido
Toshifumi Ohkusa
Tetsunori Tasaki
Kazumi Hayashi
Hideo Komita
Nobuyuki Watanabe
Yuta Suzuki
Yohei Yamamoto
Ryosuke Mori
Takao Arai
Toshihide Tanaka
Tatsuhiro Joki
Takaaki Yanagisawa
Yuichi Murayama

Background This trial was designed to evaluate the safety and clinical responses to a combination of temozolomide (TMZ) chemotherapy and immunotherapy with fusions of DCs and glioma cells in patients with glioblastoma (GBM).

Keywords:

Immunology
Dendritic cell
Temozolomide
Glioblastoma
Immunotherapy
Glioma
Chemoimmunotherapy
Biology
Chemotherapy
Oncology
in patient
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations